厄洛替尼联合调强放疗治疗局部进展期胰腺癌的疗效分析  

Clinical observation on erlotinib combined with conformal intensity modulated radiotherapy in the treatment of locally advanced pancreatic carcinoma

作　　者：曹硕[1] 王思亮[1] 杜红梅[1] 唐美月 吴荣[1] Cao Shuo Wang Siliang Du Hongmei Tang Meiyue Wu Rong(The Second Department of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang 110022, China)

机构地区：[1]中国医科大学附属盛京医院第二肿瘤病房,沈阳110022

出　　处：《中国医师进修杂志》2017年第1期30-32,共3页Chinese Journal of Postgraduates of Medicine

摘　　要：目的：观察分析厄洛替尼联合调强放疗治疗局部进展期胰腺癌的疗效和安全性。方法回顾性分析23例局部进展期胰腺癌患者的临床资料，治疗方法：口服厄洛替尼100 mg/次，1次/d，连续口服直至病情进展或出现严重不能耐受的不良反应；调强放疗剂量50.4 Gy，1次/d，1.8 Gy/次，5次/周，共28次。放疗结束后4周评价疗效和不良反应。结果23例患者中，部分缓解10例，稳定9例，进展4例，客观有效率为43.5％（10/23），中位生存时间11.3个月。不良反应包括乏力、皮疹、骨髓抑制、恶心和腹泻等，均较轻，多为Ⅰ～Ⅱ度，可耐受。结论厄洛替尼联合调强放疗治疗局部进展期胰腺癌的近期疗效及疼痛缓解情况比较理想，可以改善患者生命质量，耐受性良好。Objective To analyze the efficacy and safety of erlotinib associated conformal intensity modulated radiotherapy in treatment （IMRT） of locally advanced pancreatic carcinoma. Methods The clinical data of 23 patients with locally advanced pancreatic carcinoma were retrospectively analyzed. The patients′ therapeutic methods： erlotinib was taken continuously and orally at 100 mg/time, 1 time/d until disease progressed or serious adverse reactions happened; intensity modulated radiotherapy （IMRT） was used combined with erlotinib at 50.4 Gy, 1 time/d, 1.8 Gy/time, 5 times/week, total 28 times. Tumor response was evaluated at the end of radiotherapy after 4 weeks. Results In 23 patients, there was partial response in 10 cases, stable disease in 9 cases and progress disease in 4 cases. The objective response rate was 43.5%（10/23）, and the median survival time was 11.3 months. Adverse reactions included fatigue, rash, bone marrow suppression, nausea and diarrhea. The adverse reactions were mostly tolerable with grade 1-2. Conclusions Erlotinib combined with IMRT is safe and effective in patients with locally advanced pancreatic carcinoma, which is worthy of further study.

关 键 词：胰腺肿瘤 放射疗法 计算机辅助 厄洛替尼 

分 类 号：R735.9[医药卫生—肿瘤]